 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 3 | 4 | 7 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 4 | 4 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 3 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 5 | 6 | 11 | | 2008 | 3 | 5 | 8 | | 2009 | 4 | 6 | 10 | | 2010 | 1 | 3 | 4 | | 2011 | 3 | 6 | 9 | | 2012 | 6 | 11 | 17 | | 2013 | 7 | 8 | 15 | | 2014 | 11 | 9 | 20 | | 2015 | 8 | 9 | 17 | | 2016 | 6 | 1 | 7 | | 2017 | 8 | 6 | 14 | | 2018 | 8 | 2 | 10 | | 2019 | 6 | 6 | 12 | | 2020 | 4 | 4 | 8 | | 2021 | 8 | 5 | 13 | | 2022 | 0 | 3 | 3 | | 2023 | 3 | 0 | 3 | | 2024 | 11 | 11 | 22 | | 2025 | 3 | 5 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Leroue MK, Maddux AB, Lehmann T, Niemiec S, Mancuso CA, Khailova L, Mourani PM, Klawitter J, Davidson JA. Alteration in Indole Metabolites After Cardiopulmonary Bypass Surgery in Neonates and Infants. Crit Care Explor. 2025 May 01; 7(5):e1267.
-
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer. 2025 May; 203:108551.
-
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, Burgener EB, Koff J, Cogen JD, Bouzek DC, Hanley E, Keck A, Stout D, Bradley J, Sagel SD. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.
-
Chakraborty N, Momirov J, Radakovic A, Chatterjee S, Kirchhoff AM, Kolb AL, West TJ, Sanchez BB, Martinez-Bartolome S, Saviola A, McClatchy D, Yates JR, Chen JS, Lairson LL, Felding BH, Boger DL. Insights into Free Drug Release from Efficacious N-Acyl O-Aminophenol Duocarmycin Prodrugs. ACS Chem Biol. 2025 02 21; 20(2):442-454.
-
Wisniewski BL, Shrestha M, Bojja D, Shrestha CL, Lee CS, Ozuna H, Rayner RE, Bai S, Cormet-Boyaka E, Reynolds SD, Kopp BT. Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2025 Mar 01; 328(3):L324-L333.
-
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 May; 36(5):583-591.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
-
Baumer ZT, Newton MS, L?fstrand L, Carpio Paucar GN, Farny NG, Whitehead TA. Engineered Stop and Go T7 RNA Polymerases. ACS Synth Biol. 2024 Dec 20; 13(12):4165-4174.
-
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 Jan; 199:108040.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|